What is the current valuation of the US malabsorption syndrome market?

The market valuation was $639.31 Million in 2024. Read More

What is the projected market size for the US malabsorption syndrome market by 2035?

The projected valuation for 2035 is $1,170.0 Million. Read More

What is the expected CAGR for the US malabsorption syndrome market during the forecast period?

The expected CAGR for the market from 2025 - 2035 is 5.65%. Read More

Which companies are the key players in the US malabsorption syndrome market?

Key players include AbbVie, Takeda Pharmaceutical Company Limited, Nestle Health Science, Johnson & Johnson, Boehringer Ingelheim, Mylan N.V., Purdue Pharma L.P., and Ferring Pharmaceuticals. Read More

What are the major segments of the US malabsorption syndrome market by causative diseases?

Major segments include Celiac disease, Intestinal disorders, Lactose intolerance, and Cystic fibrosis, with valuations ranging from $20.0 Million to $350.0 Million. Read More

How is the US malabsorption syndrome market segmented by diagnosis?

The market is segmented by diagnosis into imaging studies, CT scans, and hematologic tests, with valuations from $5.0 Million to $90.0 Million. Read More

What treatment options are available in the US malabsorption syndrome market?

Treatment options include gluten-free diets, anti-inflammatory drugs, and nutritional supplements, with valuations between $35.45 Million and $227.0 Million. Read More

What are the end-user segments in the US malabsorption syndrome market?

End-user segments include hospitals, academic and research institutes, and nutrition clinics, with valuations from $63.93 Million to $460.0 Million. Read More

How does the market performance of Celiac disease compare to other segments?

Celiac disease leads the market with a valuation range of $200.0 Million to $350.0 Million, surpassing other segments. Read More

What trends are expected in the US malabsorption syndrome market by 2035?

The market is likely to experience growth driven by increasing awareness and advancements in treatment options, reaching $1,170.0 Million by 2035. Read More

US Malabsorption Syndrome Market

ID: MRFR/Pharma/11792-CR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Malabsorption Syndrome Market Trends And Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2035

US Malabsorption Syndrome Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Medical Device, BY causative diseases (USD Million)
4.1.1 Cystic fibrosis
4.1.2 Parasitic diseases
4.1.3 Intestinal disorders
4.1.4 Celiac disease
4.1.5 Others
4.1.6 Lactose intolerance
4.1.7 Whipple’s disease
4.1.8 Tropical sprue
4.1.9 Others
4.2 Medical Device, BY diagnosis (USD Million)
4.2.1 Imaging studies
4.2.2 CT scan
4.2.3 Endoscopic retrograde cholangiopancreatogram (ERCP)
4.2.4 Magnetic resonance cholangiopancreatography (MRCP)
4.2.5 Abdominal x-ray
4.2.6 Hematologic tests
4.2.7 Other tests
4.2.8 Test of fat malabsorption
4.2.9 Tests of carbohydrate absorption
4.2.10 Schilling test
4.2.11 D-xylose test
4.2.12 Test of bile salt absorption
4.2.13 C-d-xylose breath test
4.3 Medical Device, BY treatment (USD Million)
4.3.1 Gluten-free diet
4.3.2 Anti-inflammatory drugs
4.3.3 Antibiotics
4.3.4 Nutritional supplements
4.3.5 Protease and lipase supplements
4.3.6 Antidiarrheal agents
4.3.7 Others
4.4 Medical Device, BY end-user (USD Million)
4.4.1 Hospitals
4.4.2 Academic and Research Institutes
4.4.3 Pharmaceutical companies
4.4.4 Nutrition Clinics
4.4.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Medical Device
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 AbbVie (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Takeda Pharmaceutical Company Limited (JP)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Nestle Health Science (CH)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Johnson & Johnson (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Boehringer Ingelheim (DE)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Mylan N.V. (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Purdue Pharma L.P. (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Ferring Pharmaceuticals (CH)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 US MARKET ANALYSIS BY CAUSATIVE DISEASES
6.3 US MARKET ANALYSIS BY DIAGNOSIS
6.4 US MARKET ANALYSIS BY TREATMENT
6.5 US MARKET ANALYSIS BY END-USER
6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
6.7 RESEARCH PROCESS OF MRFR
6.8 DRO ANALYSIS OF MEDICAL DEVICE
6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
6.12 MEDICAL DEVICE, BY CAUSATIVE DISEASES, 2024 (% SHARE)
6.13 MEDICAL DEVICE, BY CAUSATIVE DISEASES, 2024 TO 2035 (USD Million)
6.14 MEDICAL DEVICE, BY DIAGNOSIS, 2024 (% SHARE)
6.15 MEDICAL DEVICE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
6.16 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
6.17 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
6.18 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
6.19 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 US MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY CAUSATIVE DISEASES, 2025-2035 (USD Million)
7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
7.2.3 BY TREATMENT, 2025-2035 (USD Million)
7.2.4 BY END-USER, 2025-2035 (USD Million)
7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Medical Device Market Segmentation

Medical Device By causative diseases (USD Million, 2025-2035)

Cystic fibrosis
Parasitic diseases
Intestinal disorders
Celiac disease
Others
Lactose intolerance
Whipple’s disease
Tropical sprue
Others

Medical Device By diagnosis (USD Million, 2025-2035)

Imaging studies
CT scan
Endoscopic retrograde cholangiopancreatogram (ERCP)
Magnetic resonance cholangiopancreatography (MRCP)
Abdominal x-ray
Hematologic tests
Other tests
Test of fat malabsorption
Tests of carbohydrate absorption
Schilling test
D-xylose test
Test of bile salt absorption
C-d-xylose breath test

Medical Device By treatment (USD Million, 2025-2035)

Gluten-free diet
Anti-inflammatory drugs
Antibiotics
Nutritional supplements
Protease and lipase supplements
Antidiarrheal agents
Others

Medical Device By end-user (USD Million, 2025-2035)

Hospitals
Academic and Research Institutes
Pharmaceutical companies
Nutrition Clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓